Halozyme Therapeutics (HALO) Cash from Financing Activities (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Cash from Financing Activities data on file, last reported at -$1.6 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$1.6 million, up 51.43% year-over-year; the trailing twelve-month figure through Mar 2026 was -$83.5 million (up 62.35% YoY), and the FY2025 annual result was -$85.2 million, up 61.08% from the prior year.
• Cash from Financing Activities fell to -$1.6 million in Q1 2026 per HALO's latest filing, from $239.5 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $367.8 million in Q2 2022 and troughed at -$299.0 million in Q2 2025.
• A 5-year average of -$20.7 million and a median of -$489000.0 in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities jumped 921.81% in 2022, then sank 26480.45% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $6.3 million in 2022, then tumbled by 4048.81% to -$249.9 million in 2023, then advanced by 1.4% to -$246.4 million in 2024, then soared by 197.2% to $239.5 million in 2025, then slumped by 100.67% to -$1.6 million in 2026.
• Business Quant data shows HALO's Cash from Financing Activities at -$1.6 million in Q1 2026, $239.5 million in Q4 2025, and -$22.4 million in Q3 2025.